Search results
Moffitt and Fulgent Pharma partner on personalised cancer therapies
Pharmaceutical Technology via Yahoo Finance· 19 hours agoMoffitt Cancer Center and Fulgent Pharma have announced a strategic partnership to enhance the...
Jump Financial LLC Makes New Investment in Ascendis Pharma A/S (NASDAQ:ASND)
ETF DAILY NEWS· 19 hours agoJump Financial LLC acquired a new stake in Ascendis Pharma A/S (NASDAQ:ASND – Free Report) in the fourth quarter, according to the company in its most recent disclosure with ...
FTC targets 300 Big Pharma 'junk patents,' sends warning letters to top drugmakers
BenefitsPRO· 13 hours agoThe Federal Trade Commission is stepping up its crackdown on so-called "junk patents," which it...
Royalty Pharma PLC (RPRX): A Strategic SWOT Insight
GuruFocus.com via Yahoo Finance· 6 days agoCompetition for acquiring high-quality royalties is intense and increasing. Dependence on a limited number of products and exposure to market volatility...
Shareholders in UroGen Pharma (NASDAQ:URGN) have lost 67%, as stock drops 11% this past week
Simply Wall St. via Yahoo Finance· 4 days agoWe think intelligent long term investing is the way to go. But along the way some stocks are going...
Only Four Days Left To Cash In On Royalty Pharma's (NASDAQ:RPRX) Dividend
Simply Wall St. via Yahoo Finance· 5 days agoRegular readers will know that we love our dividends at Simply Wall St, which is why it's exciting...
Perry Cleveland-Peck — Senior Publishing Editor at The Wall Street Journal
The Wall Street Journal· 3 hours agoPerry Cleveland-Peck is a senior publishing editor with The Wall Street Journal, currently based in...
Verona Pharma (NASDAQ:VRNA) Price Target Lowered to $30.00 at HC Wainwright
ETF DAILY NEWS· 2 days agoVerona Pharma (NASDAQ:VRNA – Free Report) had its price target lowered by HC Wainwright from $33.00 to $30.00 in a report published on Monday morning, Benzinga reports. HC ...
UroGen Pharma First Quarter 2024 Earnings: Misses Expectations
Simply Wall St. via Yahoo Finance· 2 days agoUroGen Pharma (NASDAQ:URGN) First Quarter 2024 Results Key Financial Results Revenue: US$18.8m (up...
Mizuho still recommends Terns Pharma as a cheap entry to the weight-loss-drug craze
Market Watch· 11 hours agoAlthough as it still has no drugs approved by the Food and Drug Administration, incremental updates...